156 related articles for article (PubMed ID: 24659663)
41. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
42. Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.
Lu T; Liu Y; Yu S; Yin C; Li P; Ye J; Ma D; Ji C
Oncotarget; 2016 Aug; 7(35):56574-56583. PubMed ID: 27489357
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
44. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
45. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
46. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
47. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
48. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
49. [Diagnostic and prognostic value of interleukin-6 in malignant non-Hodgkin's lymphomas].
Serebriakov NB; Novik AA; Shamanskiĭ SV; Krivolapov IuA; Voloshin SV; D'iakova VV; Snetkova IG; Katkova IV; Zhiburt EB
Vestn Ross Akad Med Nauk; 1998; (10):32-6. PubMed ID: 9846110
[TBL] [Abstract][Full Text] [Related]
50. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
52. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
53. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
[TBL] [Abstract][Full Text] [Related]
54. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
55. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
[TBL] [Abstract][Full Text] [Related]
56. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
Fabre-Guillevin E; Tabrizi R; Coulon V; Monnereau A; Eghbali H; Soubeyran I; Soubeyran P
Leuk Lymphoma; 2006 Apr; 47(4):603-11. PubMed ID: 16690518
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma: a single center experience.
Cil T; Altintas A; Isikdogan A; Batun S
Int J Hematol; 2009 Jul; 90(1):52-57. PubMed ID: 19472034
[TBL] [Abstract][Full Text] [Related]
58. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
Etto L; Lacerda E; Baiocchi O; Silva V; Dalboni M; Alves A; Silva M; Vettore A; Colleoni G
Leuk Lymphoma; 2008 Feb; 49(2):257-64. PubMed ID: 18231911
[TBL] [Abstract][Full Text] [Related]
59. Autoantibodies in the sera of patients with lymphoma.
Swissa M; Cohen Y; Shoenfeld Y
Leuk Lymphoma; 1992 May; 7(1-2):117-22. PubMed ID: 1472921
[TBL] [Abstract][Full Text] [Related]
60. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma.
Zhong H; Chen J; Cheng S; Chen S; Shen R; Shi Q; Xu P; Huang H; Zhang M; Wang L; Wu D; Zhao W
EBioMedicine; 2019 Mar; 41():167-174. PubMed ID: 30827933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]